Mentions
Extended reach
Total likes
Video views
AI synopsis
Several discussions highlight the findings from the article, such as a post that notes the remarkable efficacy of lenacapavir, emphasizing it 'dramatically reduced HIV infection rates compared to daily F/TDF.' Other posts echo similar sentiments, showcasing the excitement around a new 'game changer' in HIV prevention. The language used, like 'fantastic results' and 'could end the pandemic if widely deployed,' underscores a tone of optimism and urgency, effectively communicating the significance of the publication.
Many posts indicate a general support for the findings, suggesting a positive reception towards lenacapavir's efficacy.
The discussions showcase a high level of curiosity and relevant engagement with the topic, especially due to the significant advances in HIV prevention methods.
While some posts provide detailed summaries and references, others remain more superficial, indicating varied levels of investment in the discussions.
A strong belief is expressed across discussions regarding the potential for lenacapavir to significantly influence HIV prevention strategies.
In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background incidence and the incidence with emtricitabine–tenofovir disoproxil fumarate. Full trial results and Research Summary: https://t.co/yu3izOptLS https://t.co/vT2sv0iWU3
3. HIV prevention Lenacapavir is a twice-yearly subcutaneous injection, intended as prophylaxis to prevent HIV In a previous trial (in women), its efficacy was 100% In this trial (in men and gender-diverse people), its efficacy was >95% https://t.co/WD4EP3JCs9 https://t.co/ONINFdtlAf
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the results of @GileadSciences PURPOSE-2 Study. https://t.co/0FZIToS2i8
Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https://t.co/yu3izOptLS Editorial: Working at Cross-PURPOSEs to Ending HIV https://t.co/09iOGnhy5U #IDTwitter https://t.co/6dEkOm9pNI
Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https://t.co/yu3izOptLS #IDTwitter https://t.co/t0ndIkH1L1
New in the April 3, 2025, issue of NEJM: Twice-Yearly Lenacapavir for HIV Prevention (PURPOSE 2 phase 3 trial) https://t.co/yu3izOptLS Left Atrial Appendage Closure after Ablation for AF (OPTION trial) https://t.co/pWp3CpVtH4 Alteplase for Posterior Circulation Ischemic https://t.co/MwICW8LRPZ
Lenacapavir, a new long-acting HIV prevention drug, requires only two injections per year, effectively protecting against HIV for up to six months. In this video, we explore its efficacy compared to daily PrEP and…
Lenacapavir, a long-acting injectable drug, may revolutionize HIV treatment. Administered every 26 weeks, it shows a lower infection rate compared to daily oral methods, highlighting its potential in the fight against…
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine https://t.co/xtGQnJ6FKc
RT @barriere_dr: Une prévention du VIH 100% efficace mais à quel prix ! Focus par @BenjaminSire Lien
RT @barriere_dr: Une prévention du VIH 100% efficace mais à quel prix ! Focus par @BenjaminSire Lien
Une prévention du VIH 100% efficace mais à quel prix ! Focus par @BenjaminSire Lien
RT @CHIPTS: Access this paper featuring Dr. Jesse Clark, CHIPTS Development Core Director - "Twice-Yearly Lenacapavir for HIV Prevention in…
RT @CHIPTS: Access this paper featuring Dr. Jesse Clark, CHIPTS Development Core Director - "Twice-Yearly Lenacapavir for HIV Prevention in…
Access this paper featuring Dr. Jesse Clark, CHIPTS Development Core Director - "Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons." Findings showed that #HIV incidence with twice-yearly #lenacapavir was lower than incidence with F/TDF. pubmed.ncbi.nlm.nih.gov/39602624/
Access this paper featuring Dr. Jesse Clark, CHIPTS Development Core Director - "Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons." Findings showed that #HIV incidence with twice-yearly #lenacapavir was significantly lower than incidence with F/TDF. https://t.co/X3DwXZF450 https://t.co/kvYDk9ki5r
Access this paper featuring Dr. Jesse Clark, CHIPTS Development Core Director - "Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons." Findings showed that #HIV incidence with twice-yearly #lenacapavir was significantly lower than incidence with F/TDF. https://t.co/kvYDk9ki5r
Access this paper featuring Dr. Jesse Clark, CHIPTS Development Core Director - "Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons." Findings showed that #HIV incidence with twice-yearly #lenacapavir was significantly lower than incidence with F/TDF. https://t.co/kvYDk9ki5r
@cremieuxrecueil The hunt for the fabled HIV vaccine unicorn has needless delayed the more practical and possibly more effective chemo-prevention. Which is finally here. Could end the pandemic if widely deployed. https://t.co/YiTPoazg0G
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons www.nejm.org/doi/10.1056/...
A second phase 3, double-blind, randomized, active-controlled trial (NEJM)
And here: two conversions in 2,179 participants. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons www.nejm.org/doi/full/10....
@olddoctor1952 @DrSamuelBHume Yes it was in PURPOSE 2 published in @NEJM showing 96% efficacy among MSM https://t.co/0FZIToSA7G
@olddoctor1952 This trial includes US men https://t.co/HDEy4HOBeT
В другом исследовании — 3265 мужчин и небинарных персон. Lenacapavir показал такую же высокую эффективность: 2 заражения против 9 в контрольной группе. Анализ расширенной выборки (4634 человека) подтвердил тренд. https://t.co/DGtmqPCf4p
RT @DrSamuelBHume: Thank you for reading! Sources: 1. Lenacapavir 100% efficacy for HIV prevention (trial 1) https://t.co/pQC2b0zaUA 2.…
RT @DrSamuelBHume: Thank you for reading! Sources: 1. Lenacapavir 100% efficacy for HIV prevention (trial 1) https://t.co/pQC2b0zaUA 2.…
I dati dei trials più importanti: https://t.co/t3vO4b8gr6 https://t.co/RvzL6xCC91 https://t.co/DPzxvP0ZCI https://t.co/GPgApUVMxu https://t.co/iqvwca0mSD
6️⃣Artículos científicos y recursos https://t.co/lJ4mqOCcWv https://t.co/Zewoompo0e https://t.co/5Vz8rBnViw https://t.co/8VUeK2hQ4d
เอ๊า มือออโต้ไปเขียนชื่อยาแบบสลัดรวมกับยาอะไรเนี่ยผิดเลย แก้แล้วนะครับ #Lenacapavir นี่เป็น paper ของ Phase III ครับ https://t.co/Z7Io21PcLG
RT @DrSamuelBHume: Thank you for reading! Sources: 1. Lenacapavir 100% efficacy for HIV prevention (trial 1) https://t.co/pQC2b0zaUA 2.…
RT @DrSamuelBHume: Thank you for reading! Sources: 1. Lenacapavir 100% efficacy for HIV prevention (trial 1) https://t.co/pQC2b0zaUA 2.…
RT @DrSamuelBHume: Thank you for reading! Sources: 1. Lenacapavir 100% efficacy for HIV prevention (trial 1) https://t.co/pQC2b0zaUA 2.…
@DrDiGiorgio 1) TDF also still available at low cost and reduces incidence (which is pretty low) by 70% per PURPOSE2 (https://t.co/EHfQAjWpt3) 2) Even if you contract HIV, treatment (and costs) have advanced dramatically in the last 25 years.
@olddoctor1952 This trial includes US men https://t.co/HDEy4HOBeT https://t.co/QfF5hI4SE5
@davidbautistaqf https://t.co/MyZAQiQqSs
Thank you for reading! Sources: 1. Lenacapavir 100% efficacy for HIV prevention (trial 1) https://t.co/pQC2b0zaUA 2. Lenacapavir >95% efficacy for HIV prevention (trial 2) https://t.co/HDEy4HO3pl 3. Video from the AIDS conference, 2024 https://t.co/rTf7BeiHU3 4. Details on
RT @DocMuluga: Just concluded my journal club presentation of a recent paper on Lenacapavir use for HIV prevention in cisgender women. Link…
RT @DocMuluga: Just concluded my journal club presentation of a recent paper on Lenacapavir use for HIV prevention in cisgender women. Link…
RT @DocMuluga: Just concluded my journal club presentation of a recent paper on Lenacapavir use for HIV prevention in cisgender women. Link…
Just concluded my journal club presentation of a recent paper on Lenacapavir use for HIV prevention in cisgender women. Link: https://t.co/9BQCK6q369 @MildmayHospital @MildmayResearch https://t.co/sdaAwS744d
Study of PrEP: In men and gender-diverse persons, twice yearly subcutaneous lenacapavir reduced HIV incidence more than previous standard regimen of daily oral F/TDF. https://t.co/fYkLeB4p2w https://t.co/yawr47yxkD
Original Article by C.F. Kelley et al.: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 trial) nej.md/4fFWVzJ
9️⃣ Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
Original Article by C.F. Kelley et al.: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 trial) nej.md/4fFWVzJ
Lenacapavir dos veces al año para la prevención del VIH en hombres y personas de género diverso https://t.co/XIOj4GB0kb PMID 39602624
Exciting findings! In a Phase 3 trial, 816 participants received lenacapavir (26-week injections) or daily emtricitabine-tenofovir for HIV PrEP. PMID:39602624, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2411858 #Medsky #Pharmsky #RNA #ASHG #ESHG
Exciting findings! In a Phase 3 trial, 816 participants received lenacapavir (26-week injections) or daily emtricitabine-tenofovir for HIV PrEP. PMID:39602624, N Engl J Med 2025, @NEJM https://t.co/RUE8kwV1Ua #AI #Pharma #BioMed #RNA #ASHG #ESHG
Original Article by C.F. Kelley et al.: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 trial) nej.md/4fFWVzJ
RT @carpe_diem0820: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons 第3相試験では、シスジェンダー男性、トランスジェンダーの人々、ジェンダーノンバイ…
Twice-yearly lenacapavir dramatically reduced HIV infection rates compared to daily F/TDF in diverse participants without safety concerns. by Kelley CF, Acevedo-Quiñones M (...) Ogbuagu O et 52 al. in N Engl J Med https://t.co/hUxdCOr8pP #MedX #MedResearch
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background incidence and the incidence with emtricitabine–tenofovir disoproxil fumarate. Full trial results and Research Summary: nej.md/4fFWVzJ #MedSky #IDSky
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
RT @NEJM: In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background i…
In the PURPOSE 2 phase 3 trial, the incidence of HIV infection with twice-yearly lenacapavir was lower than both the background incidence and the incidence with emtricitabine–tenofovir disoproxil fumarate. Full trial results and Research Summary: https://t.co/yu3izOptLS https://t.co/vT2sv0iWU3
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine www.nejm.org/doi/full/10....
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: New in the April 3, 2025, issue of NEJM: Twice-Yearly Lenacapavir for HIV Prevention (PURPOSE 2 phase 3 trial) https://t.co/yu…
Subcut lenacapavir PrEP twice a year
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https://t.co/yu3izOptLS Editorial: Working at Cross-PURPOSEs to Ending HIV https://t.co/09iOGnhy5U #IDTwitter https://t.co/6dEkOm9pNI
RT @NEJM: New in the April 3, 2025, issue of NEJM: Twice-Yearly Lenacapavir for HIV Prevention (PURPOSE 2 phase 3 trial) https://t.co/yu…
HUGE improvement over handfuls of pills & complicated regimens: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine www.nejm.org/doi/full/10....
RT @NEJM: New in the April 3, 2025, issue of NEJM: Twice-Yearly Lenacapavir for HIV Prevention (PURPOSE 2 phase 3 trial) https://t.co/yu…
New in the April 3, 2025, issue of NEJM: Twice-Yearly Lenacapavir for HIV Prevention (PURPOSE 2 phase 3 trial) https://t.co/yu3izOptLS Left Atrial Appendage Closure after Ablation for AF (OPTION trial) https://t.co/pWp3CpVtH4 Alteplase for Posterior Circulation Ischemic https://t.co/MwICW8LRPZ
After outstanding results from PURPOSE 2 show that Lencapavir injected 2x annually protects against HIV better than oral PrEP in at risk patients, an editorial calls for pharmaceutical companies to become heroes rather than villains. https://t.co/PyADJF7DCe https://t.co/ZeFS32D1C7
"Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons." Étude PURPOSE 2. Publiée ce jour dans le @nejm.org. #MedSky #IDSky #HIV www.nejm.org/doi/full/10....
Sources HIV prevention in women: https://t.co/YHV1xnc4YZ HIV prevention in men: https://t.co/HDEy4HO3pl
長時間作用型HIVカプシド阻害剤であるLenacapavir（年2回皮下注射、1回投与で約460万円）は、TDF/FTC（毎日内服、年間約91万円、アドヒアランスが低いのが問題）よりHIV感染予防効果が高い。シスジェンダー女性以外を対象とした研究。保険適用と薬価の問題あり
New study finds twice-yearly subcutaneous lenacapavir significantly lowers #HIV incidence compared to daily #PrEP in cis men, trans women, trans men & nonbinary people.
Lenacapavir es inyectado dos veces al año. En dos estudios clínicos se encontró una tasa de éxito del 96% y el 100% en prevenir la infección. https://t.co/gZvAB7KpZL
RT @SamuelBHume: Biggest medical discoveries of the week (
https://t.co/e4BliHZw0n
@AlfonsoCdk4 @farmacotips https://t.co/nZ5TZ8Q7ZH
RT @GeSIDA_SEIMC:
RT @SamuelBHume: Biggest medical discoveries of the week (
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons - PubMed https://t.co/54NAn2CMP7
@ThulaniSundu @stats_feed Found this, it provides some clinical insight as well. Gilead has also approved licensing for generic manufacturing which will lower its cost and South Africa is on the list. https://t.co/xx9ioFM3xB
Dejo la liga de los estudios; Purpose 1: https://t.co/7gEOffzbrS Purpose 2: https://t.co/8OmrBvUBxD
Now remarkable new science. Long-acting HIV prevention more effective than oral forms -ZERO infections among African women @LindaGailBekker et al https://t.co/FS8Osa4QRH -remarkable study MSM & trans ppl: https://t.co/FnZzG7a8V9 -long-acting for KP https://t.co/zVrf6XF7B5 5/10
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine https://t.co/Df70XBTpiS
RT @ABsteward: PURPOSE 2 RCT
RT @ABsteward: PURPOSE 2 RCT
Twice-yearly lenacapavir significantly reduced HIV infections compared to daily F/TDF and the background incidence in diverse populations. by Kelley CF, Acevedo-Quiñones M (...) Cahn P et 6 al. in N Engl J Med #MedSky
Twice-yearly lenacapavir significantly reduced HIV infections compared to daily F/TDF and the background incidence in diverse populations. by Kelley CF, Acevedo-Quiñones M (...) Cahn P et 6 al. in N Engl J Med https://t.co/hUxdCOrGfn #MedX #MedResearch
RT @SamuelBHume: Biggest medical discoveries of the week (
RT @SamuelBHume: 3. HIV prevention Lenacapavir is a twice-yearly subcutaneous injection, intended as prophylaxis to prevent HIV In a prev…
RT @SamuelBHume: 3. HIV prevention Lenacapavir is a twice-yearly subcutaneous injection, intended as prophylaxis to prevent HIV In a prev…
RT @SamuelBHume: 3. HIV prevention Lenacapavir is a twice-yearly subcutaneous injection, intended as prophylaxis to prevent HIV In a prev…
RT @SamuelBHume: Biggest medical discoveries of the week (
RT @SamuelBHume: 3. HIV prevention Lenacapavir is a twice-yearly subcutaneous injection, intended as prophylaxis to prevent HIV In a prev…
RT @SamuelBHume: 3. HIV prevention Lenacapavir is a twice-yearly subcutaneous injection, intended as prophylaxis to prevent HIV In a prev…
RT @SamuelBHume: 3. HIV prevention Lenacapavir is a twice-yearly subcutaneous injection, intended as prophylaxis to prevent HIV In a prev…
RT @SamuelBHume: 3. HIV prevention Lenacapavir is a twice-yearly subcutaneous injection, intended as prophylaxis to prevent HIV In a prev…
RT @SamuelBHume: 3. HIV prevention Lenacapavir is a twice-yearly subcutaneous injection, intended as prophylaxis to prevent HIV In a prev…
RT @SamuelBHume: 3. HIV prevention Lenacapavir is a twice-yearly subcutaneous injection, intended as prophylaxis to prevent HIV In a prev…
3. HIV prevention Lenacapavir is a twice-yearly subcutaneous injection, intended as prophylaxis to prevent HIV In a previous trial (in women), its efficacy was 100% In this trial (in men and gender-diverse people), its efficacy was >95% https://t.co/WD4EP3JCs9 https://t.co/ONINFdtlAf
RT @SamuelBHume: Biggest medical discoveries of the week (
Lenacapavir, un nuevo fármaco para prevenir la infección por #VIH. Cómodo de administrar (2 inyec/año) y eficaz. Pero a un precio abusivo. Otra vez. Mientras se permita el abuso... @desdelamoncloa @Monica_Garcia_G @Seisida @GeSIDA_SEIMC @EACSociety https://t.co/yyKu5MwTsN https://t.co/UyUgXgoQ5h
RT @SamuelBHume: Biggest medical discoveries of the week (
RT @SamuelBHume: Biggest medical discoveries of the week (
RT @neolithicrumba2: @SeroTainted NEJM: https://t.co/7vCbuEFsbd AP: https://t.co/HI6gEzU6XO AIS Peru: https://t.co/MGJfzot1Pd
@SeroTainted NEJM: https://t.co/7vCbuEFsbd AP: https://t.co/HI6gEzU6XO AIS Peru: https://t.co/MGJfzot1Pd
RT @SamuelBHume: Biggest medical discoveries of the week (
RT @LindaGailBekker: Nice to see this out in NEJM: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New Engl…
Nice to see this out in NEJM: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine https://t.co/UUZTSOrrW2
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons https://t.co/Eq8tADFKZz
RT @ddunguh: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine https://t.co/j…
RT @ddunguh: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine https://t.co/j…
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine https://t.co/jBLw6RwrAM @HemOnc_Uganda
RT @gglinskii: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons https://t.co/xrWQrZ6NsD
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons 第3相試験では、シスジェンダー男性、トランスジェンダーの人々、ジェンダーノンバイナリーの人々におけるHIV予防のための半年ごとの皮下注射レナカパビルが評価された。 https://t.co/I9wgLBvy8S https://t.co/ywQeumqmos
Twice-Yearly #Lenacapavir for #HIV Prevention in #Men and Gender-Diverse Persons via @NEJM #PrEP https://t.co/zLWjq2Mi8q
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine https://t.co/RN78vNyuz2
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons https://t.co/xrWQrZ6NsD
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @GlobalPHObserv: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine https:/…
RT @GlobalPHObserv: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine https:/…
RT @GlobalPHObserv: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine https:/…
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine https://t.co/Mfu9zHDkuE
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine https://t.co/Oij6IXaNus
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
RT @NEJM: Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https:/…
Original Article: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons (PURPOSE 2 phase 3 trial) https://t.co/yu3izOptLS #IDTwitter https://t.co/t0ndIkH1L1
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine https://t.co/c7GlKYmll8
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons pubmed.ncbi.nlm.nih.gov/39602624/
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @medical_xpress: Twice-yearly Lenacapavir injections reduce #HIVInfection risk by 96%, outperforming daily oral PrEP in adherence and ef…
RT @ABsteward: PURPOSE 2 RCT
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @medical_xpress: Twice-yearly Lenacapavir injections reduce #HIVInfection risk by 96%, outperforming daily oral PrEP in adherence and ef…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @medical_xpress: Twice-yearly Lenacapavir injections reduce #HIVInfection risk by 96%, outperforming daily oral PrEP in adherence and ef…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine https://t.co/hlWPG2vltc
RT @ABsteward: PURPOSE 2 RCT
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons www.nejm.org/doi/full/10....
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @medical_xpress: Twice-yearly Lenacapavir injections reduce #HIVInfection risk by 96%, outperforming daily oral PrEP in adherence and ef…
RT @ABsteward: PURPOSE 2 RCT
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @medical_xpress: Twice-yearly Lenacapavir injections reduce #HIVInfection risk by 96%, outperforming daily oral PrEP in adherence and ef…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @ABsteward: PURPOSE 2 RCT
RT @ABsteward: PURPOSE 2 RCT
RT @ABsteward: PURPOSE 2 RCT
RT @ABsteward: PURPOSE 2 RCT
RT @medical_xpress: Twice-yearly Lenacapavir injections reduce #HIVInfection risk by 96%, outperforming daily oral PrEP in adherence and ef…
Twice-Yearly Lenacapavir for #HIV Prevention in Men and Gender-Diverse Persons www.nejm.org/doi/full/10.... (subscription req for full text) #PrEP #PURPOSE2
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | New England Journal of Medicine https://t.co/1BC81SlfLJ
RT @medical_xpress: Twice-yearly Lenacapavir injections reduce #HIVInfection risk by 96%, outperforming daily oral PrEP in adherence and ef…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @medical_xpress: Twice-yearly Lenacapavir injections reduce #HIVInfection risk by 96%, outperforming daily oral PrEP in adherence and ef…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
RT @CarlosdelRio7: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the res…
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons | NEJM. Fantastic to see in print the results of @GileadSciences PURPOSE-2 Study. https://t.co/0FZIToS2i8
RT @medical_xpress: Twice-yearly Lenacapavir injections reduce #HIVInfection risk by 96%, outperforming daily oral PrEP in adherence and ef…
RT @medical_xpress: Twice-yearly Lenacapavir injections reduce #HIVInfection risk by 96%, outperforming daily oral PrEP in adherence and ef…
RT @medical_xpress: Twice-yearly Lenacapavir injections reduce #HIVInfection risk by 96%, outperforming daily oral PrEP in adherence and ef…
Twice-yearly Lenacapavir injections reduce #HIVInfection risk by 96%, outperforming daily oral PrEP in adherence and effectivity, Emory University-led trial reports in NEJM. @EmoryUniversity @nejm https://t.co/wHAvt9jaWM https://t.co/o3ebQfUUmy
RT @ABsteward: PURPOSE 2 RCT
PURPOSE 2 RCT
PURPOSE 2 RCT